US2014088164A1PendingUtilityA1
Pharmaceutical Compositions
Est. expiryNov 24, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Danping Li
A61K 31/4192A61P 31/00A61K 9/0053A61K 9/2009A61K 31/421A61K 9/2054A61K 31/422A61K 9/2077A61K 9/2018A61P 31/04A61K 9/2013A61K 47/38
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising prior to mixing;
(a) an oxazolidinone antimicrobial agent or a pharmaceutically acceptable salt, ester, or prodrug thereof, (b) a hydroxypropylmethyl cellulose polymer, (c) a disintegrant, (d) a lubricant, (e) a binder and (f) a filler.
2 . A pharmaceutical composition comprising;
(a) an oxazolidinone antimicrobial agent or a pharmaceutically acceptable salt, ester, or prodrug thereof, (b) a hydroxypropylmethyl cellulose polymer, (c) a disintegrant, (d) a lubricant, (e) a binder, and (f) a filler.
3 . The pharmaceutical composition according to claim 2 wherein said oxazolidinone antimicrobial agent comprises a pharmaceutically acceptable amount.
4 . The pharmaceutical composition according to claim 2 wherein said oxazolidinone antimicrobial agent comprises a prophylactically effective amount.
5 . The pharmaceutical composition according to claim 2 wherein said oxazolidinone antimicrobial agent is radezolid, linezolid, torezolid, or a pharmaceutically acceptable salt or prodrug thereof.
6 . The pharmaceutical composition according to claim 5 wherein said oxazolidinone antimicrobial agent is radezolid or a pharmaceutically acceptable salt thereof.
7 . The pharmaceutical composition according to claim 6 wherein said pharmaceutically acceptable salt is a hydrochloride salt.
8 . The pharmaceutical composition according to claim 6 wherein said oxazolidinone antimicrobial agent is radezolid monohydrochloride.
9 . The pharmaceutical composition according to claim 2 wherein said hydroxypropylmethylcellulose polymer is a hydroxypropylmethylcellulose acetate succinate, which is also known by the abbreviation HPMCAS.
10 . The pharmaceutical composition according to claim 9 wherein said HPMCAS is selected from HPMCAS-M, HPMCAS-H, and mixtures thereof.
11 . The pharmaceutical composition according to claim 2 wherein said disintegrant is croscarmellose sodium.
12 . The pharmaceutical composition according to claim 2 wherein said lubricant is selected from colloidal silicon dioxide, magnesium stearate, and mixtures thereof.
13 . The pharmaceutical composition according to claim 2 wherein said binder is microcrystalline cellulose.
14 . The pharmaceutical composition according to claim 2 wherein said filler is selected from lactose monohydrate, dicalciumphosphate, and mixtures thereof.
15 . The pharmaceutical composition according to claim 2 wherein said composition comprises a physical mixture.
16 . The pharmaceutical composition according to claim 2 wherein said composition comprises an amorphous dispersion of said oxazolidinone antimicrobial agent.
17 . A pharmaceutical composition comprising
Percent
by
Ingredients
Weight
Intra Granular
Radezolid hydrochloride
20.31%
(amount as hydrochloride salt)
HPMCAS-M Spray Dried
13.28%
HPMCAS-H Spray Dried
13.28%
Croscarmellose Sodium
4.00%
Microcrystalline cellulose
11.60%
Lactose monohydrate
11.60%
Colloidal silicon dioxide
0.75%
Magnesium Stearate e.g.
0.19%
Extra Granular
Croscarmellose Sodium
1.50%
Di-Cal Phosphate (DC Grade)
23.38%
Colloidal silicon dioxide
0.06%
Magnesium Stearate e.g.
0.06%
18 . A method of treating, preventing, or reducing the risk of a microbial infection in a patient comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to claim 2 .
19 .- 26 . (canceled)
27 . The method according to claim 18 wherein said patient is a human or an animal.
28 . The method according to claim 18 wherein said patient is a human.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.